211At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation

Journal of Nuclear Medicine

Volumn 40, Issue 7, 1999, Pages 1197-1203

  Larsen, Roy H ^a   Murud, Kristin M ^b   Akabani, Gamal ^b   Hoff, Per ^b   Bruland, Øyvind S ^b   Zalutsky, Michael R ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b NONE

Author keywords

Bone pain; Bone therapy; Radiohalogenated bisphosphonates

Indexed keywords

3 ASTATO BENZAMIDE N 3 HYDROXYPROPYLIDENE 3,3 BISPHOSPHONATE AT 211; 3 IODOBENZAMIDE N 3 HYDROXYPROPYLIDENE 3,3 BISPHOSPHONATE I 131; 5 ASTATOPYRIDINE 3 AMIDE N 3 HYDROXYPROPYLIDENE 3,3 BISPHOSPHONATE AT 211; 5 IODOPYRIDINE 3 AMIDE N 3 HYDROXYPROPYLIDENE 3,3 BISPHOSPHONATE I 131; ASTATINE 211; BISPHOSPHONIC ACID DERIVATIVE; IODINE 131; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ASTATINE; RADIOACTIVE IODINE;

ACYLATION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BONE; CONTROLLED STUDY; DEHALOGENATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG STABILITY; IN VIVO STUDY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH; THYROID GLAND; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; COMPARATIVE STUDY; ISOTOPE LABELING; METABOLISM; TIME; TISSUE DISTRIBUTION;

ANIMALS; ASTATINE; BONE AND BONES; BONE NEOPLASMS; DIPHOSPHONATES; IODINE RADIOISOTOPES; ISOTOPE LABELING; MALE; MICE; MICE, INBRED BALB C; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0032587782     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Nielsen OS, Munro AJ, Tannock IF. Bone metastases: pathophysiology and management policy. Clin Oncol. 1991;9:509-524.
2. Garret R. Bone destruction in cancer. Semin Oncol. 1993;72:3433-3435.
3. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone. 1995;17(suppl):101S-105S.
4. Silberstein EB. Dosage and response in radiopharmaceutical therapy of painful osseous metastasis [editorial]. J Nucl Med. 1996;37:249-252.
5. Porter AT, McEwan AB, Power JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.
6. Fleish H. Bisphosphonates in bone disease. In: Fleish H, ed. From the Laboratory to the Patient. 2nd ed. New York, NY: The Parthenon Publishing Group; 1995.
7. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 1996;335:1785-1791.
8. de Klerk JMH, van het Schip AD, Zonnenberg BA, et al. Phase 1 study of rhenium-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med. 1996;37:244-249.
9. Eisenhut M, Berberich R, Kimmig B, et al. Iodine-131-labeled diphosphonate for palliative treatment of bone metastases: II. Preliminary clinical results with iodine-131 BDP3. J Nucl Med. 1986;27:1255-1261.
10. Wilbur DS. Radiohalogenation of proteins. An overview of radionuclides, labeling methods and reagents for conjugate labeling. Bioconjug Chem. 1992;3: 433-470.
11. Sweeney DC, Johnson GS. Radioiodine therapy for thyroid cancer. Endocrinol Metab Clin North Am. 1995;24:803-809.
12. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
13. 212Bi-EDTMP-Synthesis and biodistribution of a bone seeking alpha emitting radiopharmaceutical. J Labelled Compds Radiopharm. 1994;34:717-734.
14. 211At reaction. Appl Radiat Isot. 1996;47:135-143.
15. Garg PK, Archer GE Jr, Bigner DD, et al. Synthesis of radioiodinated N-succinimidyliodobenzoate: optimization for use in antibody labeling. Appl Radiat Isot. 1989;40:485-490.
16. Garg S, Garg PK, Zalutsky MR. N-succinimidyl 5-(trialkylstannyl)-3-pyridinecarboxylates: a new class of reagents for protein radioiodination. Bioconjug Chem. 1991;2:50-56.
17. 211At-labeling of polymer particles for radiotherapy: synthesis, purification and stability. J Labelled Compds Radiopharm. 1993;33:977-986.
18. 125I-labeled amidbisphosphonates. Nucl Med Biol. 1999: in press.
19. Hui TE, Fisher DR, Kuhn JA, et al. A mouse model for calculating cross-organ beta doses from yttrium-90-labeled immunoconjugates. Cancer. 1994;73(suppl): 951-957.
20. Nelson WR, Hirayama H, Rogers DWO. The EGS4 code system. Stanford Linear Energy Accelerator. SLAC Report 265. 1985:162-268.
21. 211At]astatide accumulation in normal tissues: preliminary evaluation of seven potential compounds. Nucl Med Biol. 1998;25:351-357.
22. Atkins HL. Overview of nuclides for bone palliation. Appl Radiat Isot. 1998;49: 277-283.
23. Ketchum LE, Green MA, Jurisson SS. Research radionuclide availability in North America. J Nucl Med. 1997;38(8):21N-28N, 47N-48N.
24. Vinholes J, Guo C-Y, Purohit OP, et al. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer. 1996;73:1089-1095.
25. 131I as labels of a monoclonal antibody and F(ab′)2 fragment Cancer Res. 1990;50:3514-3520.
26. 211At]astato-N-piperidinoethylbenzamide. Nucl Med Biol. 1995;22:467-474.
27. 211At]astato-2′-deoxyuridine, an α-particle-emitting endoradiotherapeutic agent undergoing DNA incorporation. Cancer Res. 1996;56:1204-1209.
28. 211At]astatoaniline. Nucl Med Biol. 1997;24:135-143.
29. Cal JC, Daley-Yates PT. Disposition and nephrotoxcity of 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD), in rats and mice. Toxicology. 1990;65:179-197.
30. 131I labeled diphosphonate for the palliative treatment of bone metastases: IV. Syntheses of benzylidenediphosphonates and their organ distribution in rats. Int J Rad Appl Instrum. 1987;38:535-540.
31. Eisenhut M. Iodine-131-labeled diphosphonates for the palliative treatment of bone metastases: I. Organ distribution and kinetics of I-131 BDP3 in rats. J Nucl Med. 1984;25:1356-1361.
32. Lee CK, Aeppli DM, Unger J. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases: the University of Minnesota experience. Am J Clin Oncol. 1996;19:102-107.